Rabih El Bizri, MD
Pulmonary Disease · Providence, RINPI 1154524643
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,393 of the $11,710 with a category attached, or 88.8%. 28 manufacturers reported payments, led by GSK at 26.5% of the total.
Across 522 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Boston Scientific$1K
- Sanofi$930
- Mylan Specialty L.p.$609
- plus $3K from 22 others
What the payments were for
- Travel & lodging$1,12310%
- Food & beverage$10,39389%
- Education$1942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 186 | $3,109 |
| AstraZeneca(2 entities) | 87 | $1,728 |
| Boehringer Ingelheim | 52 | $1,368 |
| Boston Scientific | 12 | $1,286 |
| Sanofi | 31 | $930 |
| Mylan Specialty L.p. | 39 | $609 |
| Grifols USA, LLC | 24 | $570 |
| Regeneron Healthcare Solutions, Inc. | 20 | $548 |
| Amgen | 7 | $179 |
| Baxter Healthcare | 7 | $163 |
| Teva Pharmaceuticals USA, Inc. | 7 | $148 |
| Verona Pharma, Inc. | 5 | $135 |
| Philips North America LLC | 5 | $129 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Sunovion Pharmaceuticals Inc. | 8 | $91 |
| Genentech USA, Inc. | 5 | $84 |
| Mallinckrodt Hospital Products Inc. | 4 | $83 |
| Electromed, Inc. | 6 | $82 |
| Insmed, Inc. | 2 | $79 |
| Johnson & Johnson(2 entities) | 2 | $51 |
| Novartis | 3 | $51 |
| Viatris Specialty LLC | 2 | $45 |
| Pfizer | 2 | $40 |
| Gilead | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Merck | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| Galvanize Therapeutics, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACQUIRE$542
- GENERAL PULMONARY$474
- DUPIXENT$116
- BREZTRI$115
How this compares
$11,710 in reported general payments places this provider in the 85th percentile of 59 pulmonary disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 206 | $144,403 |
| Dupixent PenDupilumab | 25 | $101,878 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 105 | $90,316 |
| Breo ElliptaFluticasone/Vilanterol | 107 | $43,817 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 81 | $38,888 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 77 | $36,839 |
| Spiriva RespimatTiotropium Bromide | 64 | $36,154 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $8,271 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $7,597 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $6,624 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 271 | $6,251 |
| Varenicline Tartrate | 33 | $6,213 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $5,760 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $5,745 |
| Wixela InhubFluticasone Propion/Salmeterol | 53 | $3,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $3,109 | $233,926417 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,728 | $96,939127 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,368 | $82,639159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 59 pulmonary disease providers in Rhode Island.
Other pulmonary disease in Providence
- Christopher MullinProvidence$19K
- Andrew FoderaroProvidence$7K
- Joseph MehargProvidence$4K
- Linda NiciProvidence$3K
- Vesna BuntakProvidence$2K
- Ahmed EidProvidence$2K
- Anthony LubinskyProvidence$344
- Debasree BanerjeeProvidence$122
- Navneet SinghProvidence$96
- Jisoo LeeProvidence$89
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.